5,226 Shares in Abbott Laboratories $ABT Acquired by Cambria Investment Management L.P.

Cambria Investment Management L.P. acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,226 shares of the healthcare product maker’s stock, valued at approximately $700,000.

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after acquiring an additional 2,977,715 shares during the period. State Street Corp increased its stake in shares of Abbott Laboratories by 0.9% in the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after purchasing an additional 689,517 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Abbott Laboratories by 3.8% in the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock valued at $5,184,589,000 after purchasing an additional 1,390,554 shares during the period. Norges Bank purchased a new stake in shares of Abbott Laboratories during the 2nd quarter valued at approximately $3,026,180,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Abbott Laboratories by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock worth $2,022,080,000 after buying an additional 821,325 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Royal Bank Of Canada dropped their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Leerink Partners cut their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Finally, Citigroup cut their price objective on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Trading Down 0.5%

ABT stock opened at $113.09 on Thursday. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.15. The company has a market capitalization of $196.51 billion, a PE ratio of 30.40, a price-to-earnings-growth ratio of 1.81 and a beta of 0.74. The company’s 50 day moving average price is $116.67 and its two-hundred day moving average price is $124.91. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter last year, the business earned $1.34 earnings per share. The business’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA approved Abbott’s redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader that could improve clinician workflows and patient adoption, supporting long‑term device revenue growth. How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Several insiders (senior VPs/EVPs) disclosed small sales of ABT shares on Mar. 2 — amounts are modest relative to their remaining holdings and likely represent routine portfolio management rather than a clear signal. Abbott Laboratories Insider Selling
• Neutral Sentiment: Elevated investor attention — Zacks flags ABT as drawing interest, which can amplify moves in either direction but doesn’t by itself change fundamentals. Abbott Laboratories (ABT) is Attracting Investor Attention
• Negative Sentiment: Revenue miss in the latest quarter (reported $11.46B vs. consensus ≈ $11.8B) — EPS met estimates but the top‑line shortfall and softer near‑term trends have left analysts cautious and pressured the stock. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why
• Negative Sentiment: Legal risk: Abbott is set to face trial over claims that a premature‑infant formula caused a deadly disease — a high‑visibility lawsuit that could create financial and reputational downside depending on outcomes or settlements. Abbott set to face trial over claims premature infant formula caused deadly disease

Insider Activity

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the sale, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.